Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2020 Feb;43(2):446-452.
doi: 10.2337/dc19-1065. Epub 2019 Nov 22.

Microvascular and Cardiovascular Outcomes According to Renal Function in Patients Treated With Once-Weekly Exenatide: Insights From the EXSCEL Trial

M Angelyn Bethel  1 , Robert J Mentz  2 , Peter Merrill  2 , John B Buse  3 , Juliana C Chan  4 , Shaun G Goodman  5   6 , Nayyar Iqbal  7 , Neli Jakuboniene  8 , Brian Katona  7 , Yuliya Lokhnygina  2 , Renato D Lopes  2 , Aldo P Maggioni  9 , Peter Ohman  7 , Tsvetalina Tankova  10 , George L Bakris  11 , Adrian F Hernandez  2 , Rury R Holman  12
Affiliations
Randomized Controlled Trial

Microvascular and Cardiovascular Outcomes According to Renal Function in Patients Treated With Once-Weekly Exenatide: Insights From the EXSCEL Trial

M Angelyn Bethel et al. Diabetes Care. 2020 Feb.

Abstract

Objective: To evaluate the impact of once-weekly exenatide (EQW) on microvascular and cardiovascular (CV) outcomes by baseline renal function in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL).

Research design and methods: Least squares mean difference (LSMD) in estimated glomerular filtration rate (eGFR) from baseline between the EQW and placebo groups was calculated for 13,844 participants. Cox regression models were used to estimate effects by group on incident macroalbuminuria, retinopathy, and major adverse CV events (MACE). Interval-censored time-to-event models estimated effects on renal composite 1 (40% eGFR decline, renal replacement, or renal death) and renal composite 2 (composite 1 variables plus macroalbuminuria).

Results: EQW did not change eGFR significantly (LSMD 0.21 mL/min/1.73 m2 [95% CI -0.27 to 0.70]). Macroalbuminuria occurred in 2.2% of patients in the EQW group and in 2.5% of those in the placebo group (hazard ratio [HR] 0.87 [95% CI 0.70-1.07]). Neither renal composite was reduced with EQW in unadjusted analyses, but renal composite 2 was reduced after adjustment (HR 0.85 [95% CI 0.74-0.98]). Retinopathy rates did not differ by treatment group or in the HbA1c-lowering or prior retinopathy subgroups. CV outcomes in those with eGFR <60 mL/min/1.73 m2 did not differ by group. Those with eGFR ≥60 mL/min/1.73 m2 had nominal risk reductions for MACE, all-cause mortality, and CV death, but interactions by renal function group were significant for only stroke (HR 0.74 [95% CI 0.58-0.93]; P for interaction = 0.035) and CV death (HR 1.08 [95% CI 0.85-1.38]; P for interaction = 0.031).

Conclusions: EQW had no impact on unadjusted retinopathy or renal outcomes. CV risk was modestly reduced only in those with eGFR ≥60 mL/min/1.73 m2 in analyses unadjusted for multiplicity.

PubMed Disclaimer

Figures

Figure 1
Figure 1
CV safety outcomes by baseline renal function: MACE (A) and all-cause mortality (B). MACE-3, three-item MACE composite.
See this image and copyright information in PMC

References

    1. Ninomiya T, Perkovic V, de Galan BE, et al. .; ADVANCE Collaborative Group . Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol 2009;20:1813–1821 - PMC - PubMed
    1. So WY, Kong AP, Ma RC, et al. . Glomerular filtration rate, cardiorenal end points, and all-cause mortality in type 2 diabetic patients. Diabetes Care 2006;29:2046–2052 - PubMed
    1. Perkovic V, Verdon C, Ninomiya T, et al. . The relationship between proteinuria and coronary risk: a systematic review and meta-analysis. PLoS Med 2008;5:e207. - PMC - PubMed
    1. UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) [published correction appears in Lancet 1999;354:602] Lancet 1998;352:837–853 - PubMed
    1. Turnbull FM, Abraira C, Anderson RJ, et al. .; Control Group . Intensive glucose control and macrovascular outcomes in type 2 diabetes [published correction appears in Diabetologia 2009;52:2470] Diabetologia 2009;52:2288–2298 - PubMed

Publication types

MeSH terms